Роль таргетной терапии в лечении метастатического HER-2-положительного рака молочной железы с поражением головного мозга

При прогрессировании HER-2-положительного рака молочной железы метастазы в головной мозг выявляются у 25–35 % больных. Сочетание химиотерапии с анти-HER-2-терапией повышает выживаемость даже после развития метастазов в головной мозг благодаря улучшению контроля системного заболевания. В статье представлены результаты исследований, обосновывающие использование таргетных анти-HER-2-препаратов, а также инновационного препарата T-DM1 при метастатическом поражении головного мозга.

1. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J Clin Oncol 2004;22(17):3608–17.

2. Arslan C., Dizdar O., Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 2010;11(7):1089–100.

3. Weil R.J., Palmieri D.C., Bronder J.L. et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167(4):913–20.

4. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer 2009;9(4):274–84.

5. Leone J.P., Lee A.V., Brufsky A.M. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med 2015;4(7):989–94.

6. Devriendt D., Levivier M., Hilderbrand J. Treatment of brain metastases from breast cancer. Breast Cancer Mol Med 2006:505–23.

7. Wadasadawala T., Gupta S., Bagul V., Patil N. Brain metastases from breast cancer: management approach. J Cancer Res Ther 2007;3(3):157–65.

8. Gabos Z., Sinha R., Hanson J. et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24(36):5658–63.

9. Tham Y.L., Sexton K., Kramer R. et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107(4):696–704.

10. Pestalozzi B.C., Zahrieh D., Price K.N. et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17(6):935–44.

11. Nam B.H., Kim S.Y., Han H.S. et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10(1):R20.

12. Aversa C., Rossi V., Geuna E. et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014;23(5):623–8.

13. Lee S.S., Ahn J.H., Kim M.K. et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008;111(3):523–30.

14. Sperduto P.W., Kased N., Roberge D. et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82(5): 2111–7.

15. Klos K.J., O’Neill B.P. Brain metastases. Neurologist 2004;10(1):31–46.

16. Dawood S., Broglio K., Esteva F.J. et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19(7):1242–8.

17. Gil-Gil M.J., Martinez-Garcia M., Sierra A. et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 2014;16(5):436–46.

18. Niwinska A., Pogoda K., Murawska M., Niwinski P. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 2011;37(7):635–42.

19. Swain S.M., Baselga J., Kim S.B. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724–34.

20. Goss P.E., Qi S., Josse R.G. et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34(3):384–92.

21. Goss P.E., Qi S., Cheung A.M. et al. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004;10(17):5717–23.

22. Clayton A.J., Danson S., Jolly S. et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91(4):639–43.

23. Bendell J.C., Domchek S.M., Burstein H.J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972–7.

24. Pestalozzi B.C., Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18(11):2349–51.

25. Stemmler H.J., Heinemann V. Central nervous system metastases in HER-2- overexpressing metastatic breast cancer: a treatment challenge. Oncology 2008;13(7):739–50.

26. Dijkers E.C., Oude Munnink T.H., Kosterink J.G. et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2- positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87(5):586–92.

27. Tamura K., Kurihara H., Yonemori K. et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 2013;54(11):1869–75.

28. Brufsky A.M., Mayer M., Rugo H.S. et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011;17(14):4834–43.

29. Yap Y.S., Cornelio G.H., Devi B.C. et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012;107(7):1075–82.

30. Park Y.H., Park M.J., Ji S.H. et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009;100(6):894–900.

31. Lin N.U., Carey L.A., Liu M.C. et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993–9.

32. Lin N.U., Dieras V., Paul D. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15(4):1452–9.

33. Sutherland S., Ashley S., Miles D. et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br J Cancer 2010;102(6):995–1002.

34. Metro G., Foglietta J., Russillo M. et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22(3):625–30.

35. Iwata H., Narabayashi M., Ito Y. et al. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol 2013;18(4):621–8.

36. Ro J., Park S., Kim S. et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer 2012;12:322.

37. Bachelot T., Romieu G., Campone M. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013;14(1):64–71.

38. Cameron D., Casey M., Press M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533–43.

39. Pivot X., Manikhas A., Zurawski B. et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015;33(14):1564–73.

40. Hammerman A., Greenberg-Dotan S., Feldhamer I. et al. Second-line treatment of Her2- positive metastatic breast cancer: trastuzumab beyond progression or lapatinib? A population based cohort study. PLoS ONE 2015;10(9):e0138229.

41. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613–9.

42. Klabunde C.N., Potosky A.L., Legler J.M., Warren J.L. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53(12):1258–67.

43. Gelmon K.A., Boyle F., Kaufman B. et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31. J Clin Oncol 2015;33(14):1574–83.

44. Baron J.M., Boster B.L., Barnett C.M. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract 2015;21(2):132–42.

45. Boyraz B., Sendur M.A., Aksoy S. et al. Trastuzumab emtansine (T-DM1) for HER2- positive breast cancer. Curr Med Res Opin 2013;29(4):405–14.

46. Verma S., Miles D., Gianni L. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783–91.

47. Krop I.E., Lin N.U., Blackwell K. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015;26(1):113–9.

48. Swain S.M., Baselga J., Miles D. et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014;25(6):1116–21.

49. Bartsch R., Berghoff A.S., Vogl U. et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Ann Oncol 2014;25(Suppl 4):iv122.

50. Santos A.J., Franco C.M., Borges L.R. et al. Met stases cerebrais. Rev Neurociências 2001;9(1):20–6.

51. https://clinicaltrials.gov/ct2/show/NCT02135159.